Shingrix is a recombinant zoster vaccine designed to prevent shingles (herpes zoster) and its complications. It is approved for adults aged 50 and older, as well as immunocompromised individuals aged 18 and older. Shingrix works by stimulating a strong immune response to the varicella-zoster virus, which causes shingles. The vaccine is administered in two doses, given 2 to 6 months apart. Clinical studies have shown Shingrix to be over 90% effective in preventing shingles and its painful complications, making it a highly recommended option for adults to protect against this condition.
1
Shingrix is a recombinant vaccine designed to prevent shingles (herpes zoster) and its complications, such as postherpetic neuralgia (PHN).
Shingrix is given in two doses:
Clinical studies indicate that Shingrix is over 90% effective in preventing shingles and its complications.
Common side effects, typically mild to moderate in intensity, include:
These side effects generally resolve within a few days.
Current data suggests that Shingrix provides strong protection against shingles for at least four years. Ongoing studies are evaluating the long-term efficacy of the vaccine.
Yes, Shingrix is approved and recommended for immunocompromised individuals aged 18 and older. Clinical trials have shown it to be safe and effective in this population.